Kymab Ramps Up Efforts for Antibody Partnerships, R&D
LONDON – Kymab Ltd. called up two industry veterans to help with the commercialization of its new platform technology for generating monoclonal antibodies in transgenic mice, as it prepares both to out-license access to the technology and use it to start an internal drug discovery effort.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter